Oct 30 (Reuters) - Briacell Therapeutics Corp BCT.V
* FDA approves the roll-over combination study with checkpoint inhibitor immunotherapies to allow continued access to BriaVax in patients with advanced breast cancer
* Briacell Therapeutics - FDA approved roll-over combination study of BriaVax with pembrolizumab or ipilimumab
* Briacell- FDA approved roll-over combination study for patients previously treated with BriaVax from Phase I/IIa clinical trial in advanced breast cancer